General introduction
|
|
- Justin Jennings
- 5 years ago
- Views:
Transcription
1 1 General introduction
2 10 Chapter 1
3 General Introduction Dementia Dementia is defined as an acquired impairment of cognitive function in at least two domains, including memory, which interferes with normal social or occupational performance and is not attributable to delirium or psychiatric disorders. The most commonly used criteria for the diagnosis of dementia are those defined in the DSM-IV. 1 Epidemiology Dementia is a chronic disorder that is particularly common in the elderly. Worldwide, 24.3 million people have dementia, with 4.6 million new cases of dementia every year. 2 In Europe, the prevalence of dementia in subjects aged over 65 years has been estimated to be 6.4% of the population in a meta-analysis pooling data of 11 European population-based studies. 3 Age is a major risk factor for dementia, with the prevalence nearly doubling every five years of age-increase between ages 60 and It is estimated that within the next 50 years the number of patients with dementia in Europe will rise to over 16 million, due to the increasing life-expectancy in Western society. 4 Besides the physical, social and psychological burden on carers of patients with dementia, the financial burden on society will grow exponentially too. 4 Types of dementia Dementia can be caused by various underlying diseases. The most common type of dementia is Alzheimer s disease (AD), which accounts for about 70% of cases in the elderly. The second most common cause of dementia is vascular dementia (VaD). Other, less common, causes include dementia with Lewy bodies (DLB) and frontotemporal lobar degeneration (FTLD). Below the age of 65 years dementia is far less common, and the distribution of underlying causes differs from that observed in the elderly; thus in this age-category, whilst AD remains the most common cause, the prevalence of AD is reduced to one third of patients, with VaD accounting for approximately 18%. Other types of dementia, such as FTLD are relatively more prevalent, accounting for 12% of dementia cases in these younger patients. 5 Due to overlap in clinical presentation, differentiating between the various types of dementia can be difficult in clinical practice. Alzheimer s disease Clinical features AD is characterized by an insidious onset of cognitive decline, typically starting with deficits in episodic memory. Patients and their family complain for example of forget 11
4 Chapter 1 Table 1 NINCDS-ADRDA criteria for the diagnosis of probable Alzheimer s disease 7 1. Dementia established by clinical examination and confirmed by neuropsychological tests 2. Deficits in two or more areas of cognition, including memory impairment 3. Progressive worsening of memory and other cognitive functions 4. No disturbances of consciousness 5. Onset between ages 40 and Absence of systemic disorders or other brain disease that in and of themselves could account for the progressive deficits in memory and cognition ting recent personal and family events, losing items around the house, and repetitive questioning. As the disease progresses, deficits in other cognitive domains, such as aphasia, apraxia, agnosia, visuo-spatial difficulties and executive dysfunction, arise gradually. Psychological and behavioral problems such as mood disorders, psychosis, agitation and sleep disorders, occur more frequently as the disease becomes more severe. The patient becomes increasingly dependent on others and often has to be cared for in a nursing home. The average survival in AD is typically about 6 years from the onset of symptoms to death, depending on age at onset, ranging from about 8 years in those with an onset before the age of 75 to 4 years in those with an onset after the age of 85 years. 6 Diagnosis and neuropathology In everyday practice the diagnosis of AD is made using clinical criteria, the most frequently used of which are those proposed by the National Institute of Neurological and Communicating Disorders and Stroke and the Alzheimer s Disease and Related Disorders Association (NINCDS-ADRDA) Work Group (table 1). 7 A definitive diagnosis of AD can only be made by pathological examination of the brain at autopsy or after brain biopsy. Alzheimer-type pathology is characterized by extracellular neuritic plaques, consisting of beta amyloid, and intracellular neurofibrillary tangles consisting of hyperphosphorylated tau-protein. This pathology, which in AD starts to accumulate years before the first cognitive symptoms arise, 8 is present, to a much lesser extent, in normal aging too. The staging system developed 12
5 General Introduction Table 2 Criteria for amnestic Mild Cognitive Impairment by Petersen et al Memory complaint, preferably corroborated by an informant 2. Objective memory impairment for age and education, at neuropsychological testing 3. Normal general cognition 4. Preserved activities of daily living 5. No dementia by Braak and Braak describes the extent, location and sequence of accumulating neurofibrillary tangle pathology, which in AD progresses in a typical fashion, starting in the transentorhinal and entorhinal areas, before spreading to the hippocampus, the association cortices, and the rest of the cortex. 9 The accumulation of beta amyloid and tau is associated with neuronal cell death, the result of which can be appreciated at a macroscopic level as atrophy, with widening of sulci and the ventricular system and thinning of the cortex. The focality of atrophy in AD reflects the typical pattern of progression of neuropathology. Medial temporal lobe structures, such as the hippocampus, are prominently affected in early stages of the disease. There is evidence that, besides Alzheimer-type pathology, cerebrovascular pathology plays a role in AD. The majority of subjects with late-onset AD show co-existing vascular pathology at post-mortem, 10 and previous studies have suggested that the two pathologies interact. 11,12 Mild cognitive impairment As the transition from normal aging to dementia occurs gradually, a stage exists in which subjects who are developing dementia experience cognitive decline not yet severe enough to fulfill diagnostic criteria for dementia. Several clinical definitions for this intermediate phase exist, of which the criteria for amnestic mild cognitive impairment (MCI) developed by Petersen et al. 13,14 are most frequently used (table 2). Subjects who fulfill criteria for amnestic MCI are at an increased risk of developing clinical AD at a rate of about 12% per year, as compared to 1-2% per year in the age-matched general population. 13 However, it is increasingly recognized that the application of current MCI criteria results in a heterogeneous group of subjects. Not all subjects with MCI will develop AD: some will develop other types of dementia, 13
6 Chapter 1 whereas others will remain stable or even improve. 15,16 The neuropathologic outcome of patients dying with dementia, who had a prior diagnosis of amnestic MCI, has been shown to be heterogeneous, often consisting of two or more distinct pathologic entities. 17 On the other hand, criteria for amnestic MCI exclude subjects who present with first cognitive symptoms in a non-memory domain. Recently, clinical subtypes of MCI have been proposed, based on the presence or absence of memory impairment (amnestic versus non-amnestic), and on the number of cognitive domains affected (single versus multiple domains). 18 It is presumed that subjects with single-domain amnestic MCI will mainly progress to clinical AD, but the outcome of the other subtypes remains unknown. Pathological studies have shown that subjects with amnestic MCI have increased numbers of neurofibrillary tangles in medial temporal lobe structures compared to cognitively normal controls. 19 However, many concomitant pathologic abnormalities such as argyrophilic grain disease, hippocampal sclerosis and vascular lesions were also observed. 19,20 A better understanding of the pathological processes that play a role in MCI, may lead to clues for a more accurate identification of subjects with neurodegenerative diseases in the early stages. This in turn may permit accurate and early implementation of preventive and therapeutic strategies. Magnetic resonance imaging (MRI), which allows for a non-invasive, repeatable, in vivo, assessment of brain structure, is increasingly used as a diagnostic tool in these patients. Hippocampal atrophy on MRI Additional markers adding support to clinical diagnoses of AD are sought. A wellknown diagnostic marker for AD is hippocampal atrophy on MRI. Anatomy and function of the hippocampus The hippocampus is a small, arched structure in the medial temporal lobe, bulging in the temporal horn of the lateral ventricle (figure 1). Three segments can be distinguished, a head, body and tail. Anteriorly, the hippocampal head is bordered by the amygdala, and posteriorly, the hippocampal tail disappears under the splenium of the corpus callosum. Medially, the hippocampus is bordered by the entorhinal cortex, to which it is connected via the subiculum. The hippocampus is a bilaminar structure, consisting of the cornu Ammonis (hippocampus proper) and the gyrus dentatus, with one lamina rolled up inside the other. 21 The role of the hippocampus and adjacent structures in memory function has been firmly established since the effects of bilateral medial temporal lobe resection were 14
7 General Introduction Figure 1 Anatomy of the hippocampal region 21 Coronal section through hippocampal head 1: Hippocampal head 1 : internal digitations 2: temporal horn of lateral ventricle 3: amygdala 4: uncal sulcus 5: parahippocampal gyrus 6: collateral sulcus 7: fusiform gyrus 8: inferior temporal gyrus 9: middle temporal gyrus 10: superior temporal sulcus Coronal section through hippocampal body 1: Hippocampal body, cornu Ammonis 2:hippocampal body, dentate gyrus 2 : fimbria 3:subiculum 4: parahippocampal gyrus 5: temporal horn of lateral ventricle 6: collateral sulcus 7: fusiform gyrus 8: inferior temporal gyrus 9: middle temporal gyrus 10: superior temporal sulcus Coronal section through hippocampal tail 1: Hippocampal tail, cornu Ammonis 2:hippocampal tail, dentate gyrus 3: crus of fornix 4: lateral ventricle 5: isthmus 6: anterior calcarine sulcus 7: parahippocampal gyrus 8: collateral suclus 9: collateral trigone 10: fusiforme gyrus 11: inferior temporal gyrus 12: middle temporal gyrus 13 superior temporal sulcus described in patient H.M. in the 1950 s. 23 This patient had a severe amnesia after a bilateral medial temporal lobe resection because of epilepsy. Since then animal and human studies have shown that the hippocampus is involved in all modalities of declarative memory: episodic, semantic and spatial memory. 21,24 Furthermore, the hippocampus is involved in emotional behavior, motor control and regulation of hypothalamic function. 21 Hippocampal atrophy on MRI in AD Focal atrophy in the hippocampal region on MRI has been the focus of extensive study as a marker for AD, as it reflects the typical pattern of progression of Alzheimer-type neuropathology (figure 2). Neuropathological studies have shown that hippocampal volumes, as measured using MRI, correlate well with the neuropathological burden at post-mortem. 25,26 Furthermore, hippocampal atrophy has been shown to be associated with cognitive performance and especially memory function in healthy controls and patients with AD. 27,28 Many studies initially using CT and later MRI, 15
8 Chapter 1 Figure 2 Hippocampal atrophy Coronal T1-weighted MRI scans of control subject (left) and patient with mild AD (right). Note the relatively focal hippocampal atrophy in the patient with AD in comparison with the control subject. have assessed the diagnostic value of hippocampal atrophy for AD, using various visual, linear and volumetric measurements (for overview see: 29,30 ). In a meta-analysis of studies using visual and linear measurements of medial temporal lobe atrophy (MTA) on MRI, the overall sensitivity and specificity for detection of AD compared with controls was estimated to be 85% and 88% respectively. 30 It has been suggested that the medial temporal lobe structures may be less involved in AD with a presenile onset (<65 years); 31 on the other hand, it has been speculated that hippocampal atrophy might loose its sensitivity as a marker for AD in the oldest old, 32 as hippocampal atrophy occurs, to a lesser extent, in normal aging as well. 33 Besides Alzheimer-type pathology, other types of pathology, such as vascular pathology, mesiotemporal sclerosis, argyrophyllic grain disease and other neurodegenerative diseases can affect the hippocampus too. 17,34,35 Hippocampal atrophy on MRI has also been described in subjects with non-alzheimer types of dementia This may potentially limit the diagnostic value of hippocampal atrophy as a marker for AD in the differential diagnosis with other types of dementia. Studies in MCI have shown that hippocampal atrophy is detectable before subjects are clinically demented, in parallel with the accumulation of Alzheimer-type pathology which may start decades before cognitive deficits become apparent. 8 Hippocampal volumes in MCI have been shown to be intermediate between those in normal aging and AD, and the presence of hippocampal atrophy in subjects with amnestic MCI is associated with a diagnosis of dementia at follow-up
9 General Introduction Figure 3 Small vessel disease From left to right: Normal, Confluent white matter hyperintensities, and Lacunar infarct on axial Fluid Attenuated Inversion Recovery MRI scans Longitudinal studies of hippocampal atrophy Cross-sectional studies using hippocampal volumes to differentiate between diagnostic groups have limited value, due to large inter-individual variability in brain volumes. Analysis of hippocampal volume change using serial MRI reduces this problem, as each subject is used as its own control. Rates of hippocampal atrophy in controls increase with age, and are estimated to be about 1-2% above age ,48 However, longitudinal studies have shown that in AD hippocampal atrophy rates are markedly increased to about 4-8%/year In MCI, rates of hippocampal atrophy are intermediate to those observed in controls and patients with AD, with accelerated rates in amnestic MCI predicting progression to AD. 50,51 Rate of hippocampal atrophy could be a useful tool to identify subjects at risk of developing AD. Furthermore, rates of hippocampal atrophy are promising markers of disease progression, as they have been shown to correlate with change in cognitive measures, such as the Mini-Mental State Examination (MMSE) and memory tests. 51,52 However, apart from AD itself, risk factors associated with accelerated rates of hippocampal atrophy are not yet clear. Small vessel disease White matter hyperintensities (WMH) and lacunar infarcts (lacunes) are generally viewed as evidence of microvascular pathology. Both are commonly observed on MRI throughout the cognitive spectrum (figure 3). 53,54 The clinical significance of WMH remains unclear. In both AD and normal aging, WMH have been associated with subtle cognitive deficits, especially in executive function and psychomotor speed. In MCI with concomitant WMH, an increased risk of dementia has been reported. 55 The neuropsychological correlates of lacunes remain unclear as well. 17
10 Chapter 1 Table 3 Medial temporal lobe atrophy visual rating scale by Scheltens et al. 32 Score Width of choroid fissure Width of temporal horn Height of the hippocampus 0 Normal Normal Normal 1 # Normal Normal 2 ## # $ 3 ### ## $$ 4 ### ### $$$ A score of 0 to 4 is given separately for the left and right side. (#) = increase; ($) = decrease. MRI methodology Previous studies have assessed atrophy of the hippocampal region using a variety of different methods, ranging from relatively simple visual rating scales and linear measurements using either CT or MRI to more complicated volumetric and semiautomated measurements using MRI. The methods used in this thesis are reviewed below in more detail. Medial temporal lobe atrophy scale The MTA-scale developed by Scheltens et al., 32 provides a measure for global atrophy of the medial temporal lobe, and is based on visually scoring the height of the hippocampus and the width of the surrounding CSF. The severity of MTA is scored from 0 (no atrophy) to 4 (most severe atrophy), on each side of the brain on a coronal T1-weighted MRI sequence (table 3 and figure 4). This simple scale is easy to learn and has been proven to have fair to good interrater reliability and good intra-rater reliability, and has a reasonably good correlation with hippocampal volumes measurements. 57,58 Clinical studies have shown that this measure can differentiate between AD and controls, 32 and is predictive of dementia in subjects with MCI. 42 Hippocampal volumetry Compared to visual rating scales, volumetric analysis is a more detailed method to assess accurately regional volumes of a number of brain structures, including the hippocampus. This method involves manual delineation of a region of interest on 18
11 General Introduction Figure 4 Medial temporal lobe atrophy visual rating scale Examples of medial temporal lobe atrophy (MTA) score (right hemisphere), on coronal T1-weighted MRI scans. sequential slices of a volumetrically acquired scan (figure 5). Different anatomical protocols can be used to outline the hippocampus, one of which is that designed by Jack et al. 59 The dentate gyrus, subiculum, fimbria and alveus are measured, and referred to as hippocampus. Hippocampal volume can then be computed by summing the delineated area of the region of interest on each slice, and multiplying by the slice thickness. Measuring hippocampal volumes from serially acquired scans from the same individual, provided the scans are accurately spatially matched (registered), provides a measure of change over time. This hippocampal volume loss can then be divided by the inter-scan interval to provide the rate of hippocampal atrophy, usually described as a percentage per year. Various new techniques are being developed to allow automated rather than manual assessment of hippocampal atrophy rates, 44,47,60 with the aim of reducing operator 19
12 Chapter 1 Figure 5 Hippocampal volumetry Example of manually delineated hippocampal regions of interest on coronal T1-weighted MRI scan. time and variability. However, most of these techniques still require some manual intervention and have not been tested in a clinical setting to date. Thus, manual segmentation is currently considered the gold standard for hippocampal volume analysis. Unfortunately, this is a time-consuming method that requires well-trained operators and is subject to human errors in delineation. Especially, in longitudinal analysis of volume change, uncorrelated errors on serial scans may decrease reli ability of measurements. More time-efficient and reliable techniques to measure hip pocampal volume change on MRI are needed. 20 proefschrift.indd :57:23
13 General Introduction References 1. (APA). APA. Diagnostic and statistical manual of mental disorders (DSM IV).IV ed.:apa, Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366: Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S Wancata J, Musalek M, Alexandrowicz R, Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and Eur Psychiatry 2003;18: Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 2003;74: Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST. Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol 2005;62: McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer s Disease. Neurology 1984;34: Price JL, Morris JC. Tangles and plaques in nondemented aging and preclinical Alzheimer s disease. Ann Neurol 1999;45: Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82: Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357: Nagy Z, Esiri MM, Jobst KA, et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 1997;56: Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. Jama 1997;277: Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56: Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58: Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59: Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67: Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006;63: Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256: Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006;63: Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006;63: Duvernoy HM. The human hippocampus. Springer-Verlag. Berlin Heidelberg Milner B. Disorders of learning and memory after temporal lobe lesions in man. Clin Neurosurg 1972;19: Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 1957;20: Squire LR, Stark CE, Clark RE. The medial temporal lobe. Annu Rev Neurosci 2004;27: Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002;58: Jack CR, Jr., Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58: Laakso MP, Soininen H, Partanen K, et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer s disease: correlation with memory functions. J Neural Transm Park Dis Dement Sect 1995;9: Petersen RC, Jack CR, Jr., Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000;54: Bosscher L, Scheltens P. MRI of the temporal lobe. In: Qizilbash N SL, Chui H,, editors. Evidence based dementia. Oxford: Blackwell Publishing Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1: Frisoni GB, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso MP. Structural correlates of early and late onset Alzheimer s disease: voxel based morphometric study. J Neurol Neurosurg Psychiatry 2005;76: Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in «probable» Alzheimer s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:
14 Chapter Jernigan TL, Archibald SL, Fennema-Notestine C, et al. Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging 2001;22: Cervos-Navarro J, Diemer NH. Selective vulnerability in brain hypoxia. Crit Rev Neurobiol 1991;6: Togo T, Cookson N, Dickson DW. Argyrophilic grain disease: neuropathology, frequency in a dementia brain bank and lack of relationship with apolipoprotein E. Brain Pathol 2002;12: Chan D, Fox NC, Scahill RI, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer s disease. Ann Neurol 2001;49: Frisoni GB, Laakso MP, Beltramello A, et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer s disease. Neurology 1999;52: Kril JJ, Patel S, Harding AJ, Halliday GM. Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. J Neurol Neurosurg Psychiatry 2002;72: Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer s disease, Parkinson s disease with and without dementia, and in vascular dementia: An MRI study. Neurology 1996;46: Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999;52: Jack CR, Jr., Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52: Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004;63: Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer s disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry 2002;72: Barnes J, Scahill RI, Schott JM, Frost C, Rossor MN, Fox NC. Does Alzheimer s disease affect hippocampal asymmetry? Evidence from a crosssectional and longitudinal volumetric MRI study. Dement Geriatr Cogn Disord 2005;19: Du AT, Schuff N, Kramer JH, et al. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology 2004;62: Jack CR, Jr., Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer s disease. Neurology 1998;51: Thompson PM, Hayashi KM, De Zubicaray GI, et al. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 2004;22: Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 2003;60: Jack CR, Jr., Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55: Jack CR, Jr., Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62: Hampel H, Burger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005;62: Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 2005;65: Burns JM, Church JA, Johnson DK, et al. White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch Neurol 2005;62: de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001;70: Wolf H, Ecke GM, Bettin S, Dietrich J, Gertz HJ. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int J Geriatr Psychiatry 2000;15: Scheltens P, Launer L, Barkhof F, Weinstein HC, van Gool WA. Visual assesment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 1995;242: Wahlund LO, Julin P, Johansson SE, Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Neuropsychiatry 2000:69: Rossi R, Testa C, Geroldi C, Galluzzi S, Laakso MP, Beltramello A, Soininen H, Frisoni GB. Visual assessment of medial temporal atrophy on MR films in Alzheimer s disease: comparison with volumetry. Aging Clin Exp Res. 2005;17(1): Jack CR, Jr. MRI-based hippocampal volume measurements in epilepsy. Epilepsia 1994;35 Suppl 6: S Csernansky JG, Joshi S, Wang L, et al. Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Proc Natl Acad Sci U S A 1998;95:
Neuro-Imaging in dementia: using MRI in routine work-up Prof. Philip Scheltens
Neuro-Imaging in dementia: Philip Scheltens Alzheimer Center VU University Medical Center Amsterdam The Netherlands 1 Outline of talk Current guidelines Imaging used to exclude disease Specific patterns
More informationORIGINAL CONTRIBUTION. Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease
ORIGINAL CONTRIBUTION Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease Basil H. Ridha, MRCP; Josephine Barnes, MA, PhD; Laura A. van de Pol, MD; Jonathan M. Schott, MD,
More informationVisual Rating Scale Reference Material. Lorna Harper Dementia Research Centre University College London
Visual Rating Scale Reference Material Lorna Harper Dementia Research Centre University College London Background The reference materials included in this document were compiled and used in relation to
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationEPIDEMIOLOGY AND RISK FACTORS OF DEMENTIA
v2 EPIDEMIOLOGY AND RISK FACTORS OF DEMENTIA See end of article for authors affiliations Correspondence to: W M van der Flier, Department of Neurology and Alzheimer Center, Vrije Universiteit Medical Center,
More informationPRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans
PRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans Inclusion Criteria Clinical syndrome Patients must have clinical evidence
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More informationNeuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationSUPPLEMENTARY INFORMATION In format provided by Frank et al. (JULY 2010)
Table 1 Imaging bios for Alzheimer s Visual rating High correlation with Multicenter studies have Accuracy for longitudinal hippocampus volume (R 2 been performed, but changes only at chance about 0.9,
More informationVisual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study
630 Department of linical Neuroscience, Occupational Therapy and Elderly are Research, Karolinska Institute, Huddinge University Hospital L-O Wahlund P Julin P Scheltens Department of Statistics, Stockholm
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationYin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5
More informationAlzheimer s Disease. Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby
Alzheimer s Disease Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby Florey Institute of Neuroscience and Mental Health 28-6-2013 The burden of late-onset Alzheimer
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationUSE OF LABORATORY AND IMAGING INVESTIGATIONS IN DEMENTIA
USE OF LABORATORY AND IMAGING INVESTIGATIONS IN DEMENTIA c CLINICAL See end of article for authors affiliations Correspondence to: W M van der Flier, Department of Neurology and Alzheimer Center, Vrije
More informationClinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)
Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following
More informationThe most common cause of dementia is Alzheimer disease.
ORIGINAL RESEARCH A.J. Bastos-Leite J.H. van Waesberghe A.L. Oen W.M. van der Flier P. Scheltens F. Barkhof Hippocampal Sulcus Width and Cavities: Comparison Between Patients with Alzheimer Disease and
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationNeuroimaging has traditionnally
Imaging and Alzheimer s Disease: A Review Neuroimaging in Alzheimer s disease (AD) has moved beyond the stage where it was used purely to exclude other disease processes. Structural brain magnetic resonance
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationMRI of Pathological Aging Brain
MRI of Pathological Aging Brain Yukio Miki Department of Radiology, Osaka City University A variety of pathological changes occur in the brain with aging, and many of these changes can be identified by
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationSubject Index. Band of Giacomini 22 Benton Visual Retention Test 66 68
Subject Index Adams, R.D. 4 Addenbrooke s Cognitive Examination 101 Alzheimer s disease clinical assessment histological imaging 104 neuroimaging 101 104 neuropsychological assessment 101 clinical presentation
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationNon Alzheimer Dementias
Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,
More informationTHE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME
PERNECZKY 15/06/06 14:35 Page 1 THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME R. PERNECZKY, A. KURZ Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany. Correspondence
More informationFully-automated volumetric MRI with normative ranges: Translation to clinical practice
Behavioural Neurology 21 (2009) 21 28 21 DOI 10.3233/BEN-2009-0226 IOS Press Fully-automated volumetric MRI with normative ranges: Translation to clinical practice J.B. Brewer Department of Radiology and
More informationLIMBIC SYSTEM. Dr. Amani A. Elfaki Associate Professor Department of Anatomy
LIMBIC SYSTEM Dr. Amani A. Elfaki Associate Professor Department of Anatomy Learning Objectives Define the limbic system Identify the parts of the limbic system Describe the circulation of the limbic system
More informationreview of existing studies on ASL in dementia Marion Smits, MD PhD
review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam
More informationAge, Neuropathology, and Dementia
The new england journal of medicine original article Age, Neuropathology, and Dementia George M. Savva, Ph.D., Stephen B. Wharton, F.R.C.Path., Paul G. Ince, M.D., Gillian Forster, B.Sc., Fiona E. Matthews,
More informationNeuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia
86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile
More informationMagnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer s disease
J Neurol Neurosurg Psychiatry 2001;71:441 447 441 Magnetic Resonance Unit, Veterans AVairs Medical Center (114M), University of California, San Francisco 4150, Clement Street, San Francisco, CA 94121,
More informationA Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong
A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong Outline The pathogenesis of Late life cognitive impairment A framework
More informationFrontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease
International Psychogeriatrics: page 1 of 8 C 2009 International Psychogeriatric Association doi:10.1017/s1041610209009454 Frontotemporal dementia and dementia with Lewy bodies in a case-control study
More informationc ; M. N. Rossor a a The Dementia Research Centre, The National Hospital for Neurology and Neurosurgery, London, UK
This article was downloaded by:[hosp Traumat I Rehabilitacio] On: 26 February 2008 Access Details: [subscription number 773404207] Publisher: Psychology Press Informa Ltd Registered in England and Wales
More informationProjections of future numbers of dementia cases in Australia with and without prevention
Projections of future numbers of dementia cases in Australia with and without prevention Anthony F. Jorm, Keith B.G. Dear, Nicole M. Burgess Objective: To produce projections of the number of dementia
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More information8/24/18. Dementia. Risk of Dementia Following Traumatic Brain Injury: A Review of the Literature. Media Presence. Media Presence
Risk of Dementia Following Traumatic Brain Injury: A Review of the Literature Media Presence Carlos Marquez de la Plata, Ph.D. & Jeff Schaffert, M.S. Media Presence Dementia What is dementia? Dementia
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationDifferent regional patterns of cortical thinning in. Alzheimer s disease and frontotemporal dementia (FTD) are
doi:10.1093/brain/awm016 Brain (2007), 130, 1159^1166 Different regional patterns of cortical thinning in Alzheimer s disease and frontotemporal dementia An-Tao Du, 1, * Norbert Schuff, 1,2 Joel H. Kramer,
More informationAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative
ORIGINAL RESEARCH E. Matsusue S. Sugihara S. Fujii T. Kinoshita T. Nakano E. Ohama T. Ogawa Cerebral Cortical and White Matter Lesions in Amyotrophic Lateral Sclerosis with Dementia: Correlation with MR
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Frontotemporal Lobar Degeneration Without Lobar Atrophy Keith A. Josephs, MST, MD; Jennifer L. Whitwell, PhD; Clifford R. Jack, MD; Joseph E. Parisi, MD; Dennis W. Dickson, MD Background:
More informationProbable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies
Case Report Taiwanese Journal of Psychiatry (Taipei) Vol. 25 No. 1 2011 45 Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies Sin-Yi Chen, M.D. 1, Yuan-Han
More informationNeuroimaging for Diagnosis of Psychiatric Disorders
Psychiatric Disorder Neuroimaging for Diagnosis of Psychiatric Disorders JMAJ 45(12): 538 544, 2002 Yoshio HIRAYASU Associate Professor, Department of Neuropsychiatry Kyorin University School of Medicine
More informationORIGINAL CONTRIBUTION. Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia
ORIGINAL CONTRIBUTION Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia Gregory A. Jicha, MD, PhD; Joseph E. Parisi, MD; Dennis W. Dickson, MD; Kris Johnson,
More information7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery
ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are
More informationUse of Structural Magnetic Resonance Imaging to Predict Who Will Get Alzheimer s Disease
Use of Structural Magnetic Resonance Imaging to Predict Who Will Get Alzheimer s Disease Ronald J. Killiany, PhD,* Teresa Gomez-Isla, MD, PhD, Mark Moss, PhD,* Ron Kikinis, MD, Tamas Sandor, PhD, Ferenc
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationDEMENTIA DUE TO ALZHEImer
ORIGINAL CONTRIBUTION Cognitive Decline in Prodromal Alzheimer Disease and Mild Cognitive Impairment Robert S. Wilson, PhD; Sue E. Leurgans, PhD; Patricia A. Boyle, PhD; David A. Bennett, MD Objective:
More informationEstimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale
Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Seong Hye Choi, M.D.*, Duk L. Na, M.D., Byung Hwa Lee, M.A., Dong-Seog Hahm, M.D., Jee Hyang Jeong, M.D.,
More informationOLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.
Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationNEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.
NEXT-Link DEMENTIA A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA NEXT-Link DEMENTIA is a network of Danish
More informationNormal Aging of the brain
Normal Aging of the brain Marco Essig MD Prof. of Radiology, University of Heidelberg Department of Radiology, German Cancer Research Center Im Neuenheimer Feld 280, D-69120 Heidelberg Germany Contact:
More informationDementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings
Dementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings Chapter 4.2 N. Tolboom E.L.G.E. Koedam J.M. Schott M. Yaqub M.A. Blankenstein F. Barkhof Y.A.L. Pijnenburg A.A. Lammertsma
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationdoi: /brain/awq048 Brain 2010: 133;
doi:10.1093/brain/awq048 Brain 2010: 133; 1163 1172 1163 BRAIN A JOURNAL OF NEUROLOGY A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline Tom
More informationNIH Public Access Author Manuscript Metab Brain Dis. Author manuscript; available in PMC 2011 October 24.
NIH Public Access Author Manuscript Published in final edited form as: Metab Brain Dis. 2006 September ; 21(2-3): 235 240. doi:10.1007/s11011-006-9017-2. Risk factors for incident Alzheimer s disease in
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationbrain MRI for neuropsychiatrists: what do you need to know
brain MRI for neuropsychiatrists: what do you need to know Christoforos Stoupis, MD, PhD Department of Radiology, Spital Maennedorf, Zurich & Inselspital, University of Bern, Switzerland c.stoupis@spitalmaennedorf.ch
More informationPiano playing skills in a patient with frontotemporal dementia: A longitudinal case study
International Symposium on Performance Science ISBN 978-94-90306-01-4 The Author 2009, Published by the AEC All rights reserved Piano playing skills in a patient with frontotemporal dementia: A longitudinal
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationPsychology, 3 Department of Anatomy, Histology and Embryology,
PROCEEDINGS OF THE BALKAN SCIENTIFIC CONFERENCE OF BIOLOGY IN PLOVDIV (BULGARIA) FROM 19 TH TILL 21 ST OF MAY 2005 (EDS B. GRUEV, M. NIKOLOVA AND A. DONEV), 2005 (P. 115 124) QUANTITATIVE CEREBRAL ANATOMY
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationOverview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?
Neuropsychological assessment of older adults: what, when and why? Benjamin Mast, Ph.D. Associate Professor & Vice Chair, Psychological & Brain Sciences Associate Clinical Professor, Family & Geriatric
More informationORIGINAL CONTRIBUTION. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment
ORIGINAL CONTRIBUTION Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment David F. Tang-Wai, MDCM; David S. Knopman, MD; Yonas E. Geda, MD;
More informationAlzheimer disease (AD) is the most common form of dementia
ORIGINAL RESEARCH F.L. Giesel H.K. Hahn P.A. Thomann E. Widjaja E. Wignall H. von Tengg-Kobligk J. Pantel P.D. Griffiths H.O. Peitgen J. Schroder M. Essig Temporal Horn Index and Volume of Medial Temporal
More informationDifferential Diagnosis
Differential Diagnosis 2 2.1 Introduction AD accounts for up to 75 % of all dementia cases. The differential diagnosis with other conditions is sometimes challenging since several disorders may produce
More informationType 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky
Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationFour Tissue Segmentation in ADNI II
Four Tissue Segmentation in ADNI II Charles DeCarli, MD, Pauline Maillard, PhD, Evan Fletcher, PhD Department of Neurology and Center for Neuroscience, University of California at Davis Summary Table of
More informationORIGINAL CONTRIBUTION. Risk Factors for Mild Cognitive Impairment. study the Cardiovascular Health Study Cognition Study.
Risk Factors for Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study Part 2 ORIGINAL CONTRIBUTION Oscar L. Lopez, MD; William J. Jagust; Corinne Dulberg, PhD; James T. Becker,
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationChapter 1. Introduction
The older people get, the bigger the chance of losing cognitive abilities and ultimately to develop dementia. Increasing age is the largest known risk factor of dementia, with a prevalence of 1% in people
More informationDementia and Alzheimer s disease
Since 1960 Medicine Korat โรงพยาบาลมหาราชนครราชส มา Dementia and Alzheimer s disease Concise Reviews PAWUT MEKAWICHAI MD DEPARTMENT of MEDICINE MAHARAT NAKHON RATCHASIMA HOSPITAL 1 Prevalence Increase
More informationBaseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston
Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,
More informationSupplementary Online Content
Supplementary Online Content Hooshmand B, Magialasche F, Kalpouzos G, et al. Association of vitamin B, folate, and sulfur amino acids with brain magnetic resonance imaging measures in older adults: a longitudinal
More informationI n the past three decades various cognitive screening
700 PAPER The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia E F J Meulen, B Schmand, J P van Campen, S J de Koning, R W Ponds, P Scheltens, F R Verhey...
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationSilent Cerebral Strokes: Clinical Outcomes and Management
Silent Cerebral Strokes: Clinical Outcomes and Management Nagaendran Kandiah Senior Consultant Neurologist, National Neuroscience Institute, Singapore Clinician Scientist, National Medical Research Council,
More informationWhite matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration
White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,
More informationForm A3: Subject Family History
Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician
More informationDisentangling Delirium and Dementia
Disentangling Delirium and Dementia Sharon K. Inouye, M.D., M.P.H. Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Milton and Shirley F. Levy Family Chair Director, Aging
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationMild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD
AD is a Neurodegenerative Disease as Seen in the PET Scan and is Characterized by Amyloid Plaques and Neurofibrillary Tangles Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for
More informationAnatomic localization of the transentorhinal region of the perirhinal cortex
Neurobiology of Aging 29 (2008) 1591 1596 Brief communication Anatomic localization of the transentorhinal region of the perirhinal cortex Kirsten I. Taylor a,b,, Alphonse Probst c,a a Memory Clinic, Neuropsychology
More informationConfronting the Clinical Challenges of Frontotemporal Dementia
Confronting the Clinical Challenges of Frontotemporal Dementia A look at FTD s symptoms, pathophysiology, subtypes, as well as the latest from imaging studies. By Zac Haughn, Senior Associate Editor Ask
More informationBrain Health and Risk Factors for Dementia
Welcome To Brain Health and Risk Factors for Dementia Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa April 4, 2018 10:00 11:00
More information